RT Journal Article SR Electronic T1 Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy JF BMJ Case Reports FD BMJ Publishing Group Ltd SP bcr2014204950 DO 10.1136/bcr-2014-204950 VO 2014 A1 Samantha C Lee A1 John Feenstra A1 Paul R Georghiou YR 2014 UL http://casereports.bmj.com/content/2014/bcr-2014-204950.abstract AB Ruxolitinib is a novel inhibitor of the Janus kinase (JAK) pathway that has become available for the treatment of myelofibrosis. There are increasing reports of opportunistic infections associated with ruxolitinib therapy. We present a case of Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. Clinicians should consider the use of pneumocystis prophylaxis when using ruxolitinib.